Noticing signs of puberty in a young child can be a confusing and concerning experience for parents. Whether it involves physical changes like growth spurts or emotional shifts that seem out of sync with a child’s age, precocious puberty can make a child feel different from their peers. Beyond the social and emotional challenges, early development can impact long-term physical health, particularly final adult height.

Treatment is designed to press “pause” on this rapid development. By halting the progression of puberty, medical intervention allows a child’s bones to mature at a normal rate, preventing growth plates from fusing too early. This helps ensure the child reaches their full potential height. Because the causes of early puberty vary, ranging from the brain sending signals too early (central) to glands acting independently (peripheral), treatment plans are highly specific. Decisions regarding medication depend on the child’s age, the speed of progression, and predicted adult height (National Institute of Child Health and Human Development, 2021).

Overview of treatment options for Precocious Puberty

The treatment strategy for precocious puberty is determined by the underlying type. The most common form, central precocious puberty (CPP), is driven by the brain’s premature release of hormones. The standard treatment for CPP involves medication that suppresses this hormonal signaling.

For peripheral precocious puberty, which stems from ovaries, testicles, or adrenal glands producing hormones on their own, treatment focuses on the underlying cause, such as removing a tumor or blocking the action of sex hormones. In some cases, if the progression is slow and does not threaten adult height, doctors may recommend a “watch and wait” approach rather than immediate medication. However, when treatment is necessary, pharmacological intervention is the primary tool used to stop physical maturation.

Medications used for Precocious Puberty

For central precocious puberty, the gold standard of treatment is a class of drugs known as gonadotropin-releasing hormone (GnRH) analogues. These synthetic hormones look similar to the body’s natural hormones but act as a brake on the system. Common examples include leuprolide and triptorelin.

These medications are typically administered as injections. Depending on the specific formulation and family preference, injections may be given monthly, every three months, or every six months. Another option is a small, flexible implant called histrelin, which is placed under the skin of the upper arm and lasts for about a year.

Clinical experience suggests that within the first year of treatment, the rapid growth of bone age slows down, and physical signs of puberty, such as breast development or testicular enlargement, stop progressing or even regress. In cases of peripheral puberty, treatment might involve different medications like aromatase inhibitors or antiandrogens, which block the production or effects of estrogen and testosterone, respectively (Mayo Clinic, 2023).

How these medications work

GnRH analogues work by desensitizing the pituitary gland. Normally, the hypothalamus releases GnRH in pulses to tell the pituitary gland to trigger puberty. When a steady dose of a GnRH analogue is introduced, the pituitary gland initially responds but then becomes overwhelmed and stops producing the signaling hormones (LH and FSH).

By shutting down the production of LH and FSH, the message never reaches the ovaries or testicles. Consequently, the production of sex hormones (estrogen and testosterone) drops to prepubertal levels. This effectively halts the physical changes of puberty and slows down the rapid maturation of the bones, buying the child more time to grow before their growth plates close.

Side effects and safety considerations

GnRH analogues are generally safe with mild side effects, most commonly injection site pain, redness, or swelling. Some children may experience headaches, mood swings, or hot flashes due to the sudden drop in sex hormones.

Parents should be aware that symptoms, including light vaginal bleeding in girls, may briefly worsen initially before improving. Long-term data is positive; puberty and fertility resume normally after treatment stops. Monitoring requires regular blood tests and bone age X-rays. Seek medical attention if the injection site becomes infected or if signs of puberty return during treatment (MedlinePlus, 2022).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Mayo Clinic. https://www.mayoclinic.org
  2. MedlinePlus. https://medlineplus.gov
  3. National Institute of Child Health and Human Development. https://www.nichd.nih.gov
  4. National Organization for Rare Disorders. https://rarediseases.org

Medications for Precocious Puberty

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Precocious Puberty.

Found 4 Approved Drugs for Precocious Puberty

Triptodur

Generic Name
Triptorelin

Triptodur

Generic Name
Triptorelin
TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). TRIPTODUR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years and older with central precocious puberty. ( 1 )

Leuprolide Acetate

Brand Names
Vabrinty, Lutrate, Fensolvi, Lupron Depot-PED, Lupron, Eligard

Leuprolide Acetate

Brand Names
Vabrinty, Lutrate, Fensolvi, Lupron Depot-PED, Lupron, Eligard
VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )

Supprelin

Generic Name
Histrelin acetate

Supprelin

Generic Name
Histrelin acetate
SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. SUPPRELIN LA is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of children with central precocious puberty (CPP) ( 1 ).

Synarel

Generic Name
Nafarelin acetate

Synarel

Generic Name
Nafarelin acetate
FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. FOR ENDOMETRIOSIS (For Central Precocious Puberty, See Reverse Side ) SYNAREL is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. Experience with SYNAREL for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances